Mupadolimab, a novel therapeutic, is attracting considerable interest within the research community due to its unique mechanism of action. This CD73-blocking compound primarily inhibits CD73, an membrane enzyme https://socialrus.com/story24987460/a-new-mupadolimab-an-potential-cd73-targeted-antibody-shows-promise